Objective: This study aimed to compare the diagnostic performance of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in the patients with various oncological and non-oncological lesions.Patients and Methods: A total of 123 patients underwent contemporaneous 68 Ga-FAPI-04 and 18 F-FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, speci city, predictive values and accuracy of 18 F-FDG and 68 Ga-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the diagnostic e cacy.Results: The study subjects consisted of 123 patients (69 men and 54 women; mean age: 56.11±11.94). A total of 84 patients with 88 solid primary malignant tumors, 58 patients with 376 nodal metastases, 43 patients with 406 distant metastases, 8 patients with hematological neoplasms and 52 patients with 145 non-oncological lesions and benign tumors were detected. 68 Ga-FAPI-04 PET/CT demonstrated a signi cantly higher uptake and detection rate for the primary (SUVmax: 10.98±5.83 vs. 8.36±6.43, p 0.001; X 2 =0.538, p=0.021), nodal (SUVmax: 10.50±5.98 vs. 8.20±6.29, p=0.011; X 2 =2.067, p 0.001) and distant metastatic lesions (SUVmax: 6.74±4.83 vs. 9.64±6.45; p 0.001; X 2 =4.897, p 0.001) of solid tumor than did 18 F-FDG PET/CT. 68 Ga-FAPI-04 PET/CT demonstrated a lower activity (SUVmax: 6.84±4.67 vs. 13.09±7.29, p 0.001) and detection rate (X 2 =5.166, p 0.001) for multiple myeloma and lymphoma compared to 18 F-FDG PET/CT. 68 Ga-FAPI-04 and 18 F-FDG PET/CT PET/CT demonstrated a comparative diagnostic e cacy (SUVmax: 6.40±3.95 vs. 5.74±15.78, p = 0.729; X 2 = 9.460, p = 0.007) for nononcological lesion and benign tumor detection.Conclusions: Except for myeloma and lymphoma, 68 Ga-FAPI-04 PET/CT showed a superior diagnostic e cacy for detecting various primary and metastatic lesions than 18 F-FDG PET/CT. A comparative diagnostic utility for nononcological lesion detection was obtained with both tracers. 68 Ga-FAPI-04 could be used as a broad-spectrum tumor and in ammatory imaging agent in the clinical especially for various solid tumors and non-oncological lesions.
PurposeThe present retrospective analysis sought to compare the relative diagnostic efficacy of [68Ga]Ga-DOTA-FAPI-04 to that of [18F]FDG PET/CT as a means of detecting bone metastases in patients with a range of cancer types.MaterialsIn total, 30 patients with bone metastases associated with different underlying malignancies were retrospectively enrolled. All patients had undergone [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT, and the McNemar test was used to compare the relative diagnostic performance of these two imaging modalities. The maximum standard uptake value (SUVmax) was used to quantify radiotracer uptake by metastatic lesions, with the relative uptake associated with these two imaging strategies being compared via the Mann-Whitney U test. The cohort was further respectively divided into two (osteolytic and osteoblastic bone metastases) and three clinical subgroups (lung cancer, thyroid cancer, and liver cancer).Results[68Ga]Ga-DOTA-FAPI-04 PET/CT was found to be significantly more sensitive as a means of diagnosing bone metastases relative to [18F]FDG PET/CT ([109/109] 100% vs [89/109] 81.7%; P< 0.01), consistent with the significantly increased uptake of [68Ga]Ga-DOTA-FAPI-04 by these metastatic lesions relative to that of [18F]FDG (n=109, median SUVmax, 9.1 vs. 4.5; P< 0.01). [68Ga]Ga-DOTA-FAPI-04 accumulation was significantly higher than that of [18F]FDG in both osteolytic (n=66, median SUVmax, 10.6 vs 6.1; P < 0.01), and osteoblastic metastases (n=43, median SUVmax, 7.7 vs 3.7; P < 0.01). [68Ga]Ga-DOTA-FAPI-04 uptakes were significantly higher than that of [18F]FDG in bone metastases from lung cancer (n = 62, median SUVmax, 10.7 vs 5.2; P < 0.01), thyroid cancer (n = 18, median SUVmax, 5.65 vs 2.1; P < 0.01) and liver cancer (n = 12, median SUVmax, 5.65 vs 3.05; P < 0.01). However, [68Ga]Ga-DOTA-FAPI-04 detected 10 false-positive lesions, while only 5 false-positive were visualized by [18F]FDG PET/CT.Conclusion[68Ga]Ga-DOTA-FAPI-04 PET/CT exhibits excellent diagnostic performance as a means of detecting bone metastases, and is superior to [18F]FDG PET/CT in this diagnostic context. Furthermore, [68Ga]Ga-DOTA-FAPI-04 tracer uptake levels are higher than those of [18F]FDG for most bone metastases. However, owing to the potential for false-positive bone lesions, it is critical that physicians interpret all CT findings with caution to ensure diagnostic accuracy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.